A follow up study of warning letters issued by US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a situational analysis during COVID-19 pandemic
DOI:
https://doi.org/10.18203/2320-6012.ijrms20250986Keywords:
CGMP, COVID-19, Sponsors, Warning lettersAbstract
Background: United States food and drug administration (FDA) is the apex body governing and regulating clinical research. FDA issues warning letters (WLs) to individuals and institutions for significant regulatory violations. Our study aimed to evaluate the WLs issued to various stake holders during COVID-19 pandemic.
Methods: A web-based analytical study was employed to analyse WLs issued between 01 January 2020 to 31 December 2022 to clinical investigators, institutional review board (IRB) and sponsors. The outcome measures were: total number of WLs, violation theme and trend analysis in comparison with the previous study.
Results: A total of 241 WLs were analyzed which included 232 (96.27%) letters to sponsors, 9 (3.73%) to clinical investigator and none to IRB. Device-related violations were failure to comply with current good manufacturing practice (CGMP) (26/39, 66.67%; 8/14, 57.14%), adulterated/misbranded products (19/39, 48.71%; 7/14, 50%) and failure to follow monitoring schedule (16/39, 41.02%; 5/14, 35.71%) in 2020 and 2022 respectively. While in 2021, failure to submit investigational device exemption (50/61, 81.87%) was the commonest theme. In the drug-related group, violation trends were similar for 2020, 2021 and 2022. The frequent violations were misbranded/unapproved drug (24/26, 92.3%; 15/21, 71.43%; 40/57, 70.17%) and failure to comply with CGMP (8/26, 30.77%; 8/21, 38.09%; 19/57, 33.33%). Our previous study of 2015 is at variance, highlighting deviations as failure to follow monitoring schedule, failure to obtain investigator agreement and failure to maintain data record.
Conclusions: Majority warning letters were issued to sponsors, pertaining to quality and process of drug and device related research.
Metrics
References
US Food and Drug Administration-About Warning and Close-Out Letters. Available at: www. fda.gov/ inspections-compliance. Accessed on 21 December 2024.
US Food and Drug Administration-Regulatory Procedures Manual. Chapter 4 Advisory actions. Available at: www.fda.gov/media. Accessed on 22 December 2024.
US Food and Drug Administration-FDA’s Role: ClinicalTrials.gov Information Available from: https://www.fda.gov/science-research. Accessed on 18 September 2024.
Shetty YC, Saiyed AA. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study. J Med Ethics 2015;41(5):398-403. DOI: https://doi.org/10.1136/medethics-2013-101829
Kwiecinski G. An Analysis of FDA Warning Letter Citations from 2019-2023. J Pharma Innov. 2024;19(6):78. DOI: https://doi.org/10.1007/s12247-024-09879-x
Guideline IH. Guideline for good clinical practice E6 (R1). ICH Harmon Tripart Guidel. 1996;4:34.
Bramstedt KA. Unicorn poo and blessed waters: COVID 19 quackery and FDA warning letters. Ther Innov Regul Sci. 2021(55):239–44. DOI: https://doi.org/10.1007/s43441-020-00224-1
Cooper L, Lee I, Lechner D W. COVID-19 pandemic response varies by clinical trial sponsor type. Journal of Clin Transl Sci. 2021;5(1):111. DOI: https://doi.org/10.1017/cts.2021.25
Bablani S, Janodia MD. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A retrospective study. Ther Innov Regul Sci. 2020;54(4):925-31. DOI: https://doi.org/10.1007/s43441-019-00109-y
Kavyashree A, Hiremath P, Fernandes F, Muragundi P. A cross-sectional study of USFDA warning letters issued for cGMP violations pertaining to medical devices. J Appl Pharm Sci. 2020;10(5):49–53. DOI: https://doi.org/10.7324/JAPS.2020.10507
Saxena U, Bose D, Saha S, Gogtay NJ, Thatte UM. An audit of US FDA warning letters issued to sponsors, instit1587-1593utional review boards and investigators over a six-year period. Indian J Med Ethics 2022;7(2):108-13. DOI: https://doi.org/10.20529/IJME.2021.094
Downloads
Published
How to Cite
Issue
Section
